In this study, we aimed to explore protein expression profiles in the hippocampus of rats after the induction of focal ischemia injury. Forty SD male rats were randomly divided into 4 groups, with ten rats per group: the control, Day 3, Day 7, and Day 14 after the ischemia injury surgery. Focal cortical ischemia was induced in thirty rats by photothrombosis of the cortical microvessels. After surgery, the induction of ischemia was confirmed by the measurement of infarct size using 2,3,5-triphenyltetrazolium chloride (TTC) staining. In order to identify the differentially expressed proteins between the diseased and control sides of the hippocampus, a comparative proteome analysis was performed using isobaric tags for relative or absolute quantitation (iTRAQ) coupled with 2D LC-MS/MS analysis. We identified 4,081 proteins, 260 of which were non-redundant and showed differential expression between the three surgery groups and the control. The hierarchical cluster analysis indicated that the three surgery groups had markedly different expression patterns of these 260 proteins, including 160 upregulated and 80 downregulated proteins. A Gene Ontology (GO) analysis revealed 4,944 GO terms, among which myelin sheath and cell junction were the two most enriched items. In the KEGG pathway analysis, ribosome was the most abundant item. A Venn diagram showing the overlap of 25 of the differentially expressed proteins quantified from the four groups and the results from the KEGG pathway analysis suggested that Epstein–Barr virus infection was the most abundant item. In protein–protein interaction (PPI) network, a total of 223 interactive proteins were predicted and used to construct the PPI network. In conclusion, myelin sheath, cell junction, and Epstein–Barr virus infection were implicated in focal ischemia injury. Vimentin (Vim) and albumin (Alb) may be important proteins involved in focal ischemia injury.
AdibhatlaR.M. and HatcherJ.F., Altered lipid metabolism in brain injury and disorders, Sub-Cellular Biochemistry49 (2008), 241–268. doi:10.1007/978-1-4020-8831-5_9.
2.
AggarwalK., ChoeL.H. and LeeK.H., Shotgun proteomics using the iTRAQ isobaric tags, Brief Funct Genomic Proteomic5 (2006), 112–120. doi:10.1093/bfgp/ell018.
3.
BeagleholeR. and JacksonR., Alcohol, cardiovascular diseases and all causes of death: A review of the epidemiological evidence, Drug & Alcohol Review11 (1992), 275. doi:10.1080/09595239200185811.
4.
BelayevL., SaulI., HuhP.W., FinottiN., ZhaoW., BustoR. and GinsbergM.D., Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats, Brain Res845 (1999), 107–111. doi:10.1016/S0006-8993(99)01952-6.
5.
BrownellS.E., BeckerR.A. and SteinmanL., The protective and therapeutic function of small heat shock proteins in neurological diseases, Front Immunol3 (2012).
6.
Casado-VelaJ., Martínez-EstesoM.J., RodriguezE., BorrásE., ElortzaF. and Bru-MartínezR., ITRAQ-based quantitative analysis of protein mixtures with large fold change and dynamic range, Proteomics10 (2010), 343–347. doi:10.1002/pmic.200900509.
7.
ChenC.Y., HoA., HuangH.Y., JuanH.F. and HuangH.C., Dissecting the human protein–protein interaction network via phylogenetic decomposition, Scientific Reports, 4 (2014), 7153.
8.
GeP., MaC., WangS., GaoL., LiX., GuoG., MaW. and YanY., Comparative proteomic analysis of grain development in two spring wheat varieties under drought stress, Analytical and Bioanalytical Chemistry402 (2012), 1297–1313. doi:10.1007/s00216-011-5532-z.
9.
GiorginoF., LeonardiniA. and LaviolaL., Cardiovascular disease and glycemic control in type 2 diabetes: Now that the dust is settling from large clinical trials, Annals of the New York Academy of Sciences1281 (2013), 36–50. doi:10.1111/nyas.12044.
10.
GrannemanS. and BasergaS.J., Ribosome biogenesis: Of knobs and RNA processing, Experimental Cell Research296 (2004), 43–50. doi:10.1016/j.yexcr.2004.03.016.
11.
HaleyN.J., SepkovicD.W., HoffmannD. and WynderE.L., Cigarette smoking as a risk for cardiovascular disease. Part VI. Compensation with nicotine availability as a single variable, Clinical Pharmacology & Therapeutics38 (1985), 164–170. doi:10.1038/clpt.1985.153.
12.
Hyung-SeokK., Man-SeokP., Jeong-KilL., Hye-JeongK., Jong-TaeP. and Min-CheolL., Time point expression of apoptosis regulatory proteins in a photochemically-induced focal cerebral ischemic rat brain, Chonnam Medical Journal47 (2011), 144–149. doi:10.4068/cmj.2011.47.3.144.
13.
IrvineA.D. and McLeanW.H., Human keratin diseases: The increasing spectrum of disease and subtlety of the phenotype-genotype correlation, Br J Dermatol140 (1999), 815–828. doi:10.1046/j.1365-2133.1999.02810.x.
14.
IsozumiK., Obesity as a risk factor for cerebrovascular disease, Keio Journal of Medicine53 (2004), 7. doi:10.2302/kjm.53.7.
15.
KindyM.S., BhatA.N. and BhatN.R., Transient ischemia stimulates glial fibrillary acid protein and vimentin gene expression in the gerbil neocortex, striatum and hippocampus, Brain Res Mol Brain Res13 (1992), 199–206. doi:10.1016/0169-328X(92)90027-9.
16.
LankaduraiB.P., NagatoE.G. and SimpsonM.J., Environmental metabolomics: An emerging approach to study organism responses to environmental stressors, Environmental Reviews21 (2013), 180–205. doi:10.1139/er-2013-0011.
17.
LopezrodriguezA.B., AcazfonsecaE., ViverosM.P. and GarciaseguraL.M., Changes in cannabinoid receptors, aquaporin 4 and vimentin expression after traumatic brain injury in adolescent male mice, association with edema and neurological deficit, PloS One10 (2015), e0128782.
18.
MessanaI. and KašičkaV., Analysis of peptides by separation and mass spectrometric methods, Journal of Separation Science31 (2008), 425–426. doi:10.1002/jssc.200890011.
19.
MuthT., KellerD., PuetzS.M., MartensL., SickmannA. and BoehmA.M., jTraqX: A free, platform independent tool for isobaric tag quantitation at the protein level, Proteomics10 (2010), 1223–1225. doi:10.1002/pmic.200900374.
20.
NoirelJ., EvansC., SalimM., MukherjeeJ., Yen OwS., PandhalJ., Khoa PhamT., BiggsA.C. and WrightC.P., Methods in quantitative proteomics: Setting iTRAQ on the right track, Current Proteomics8 (2011), 17–30. doi:10.2174/157016411794697408.
21.
OjhaJ., KarmegamR.V., MasilamoniJ.G., TerryA.V. and CashikarA.G., Behavioral defects in chaperone-deficient Alzheimer's disease model mice, Plos One6 (2011), e16550.
22.
OwS., CardonaT., TatonA., MagnusonA., LindbladP., StensjoK. and WrightP., Quantitative shotgun proteomics of enriched heterocysts from Nostoc sp. PCC 7120 using 8-plex isobaric peptide tags, Journal of Proteome Research7 (2009), 1615–1628. doi:10.1021/pr700604v.
23.
PantoniL. and PoggesiA.D., Cognitive decline and dementia related to cerebrovascular diseases: Some evidence and concepts, Cerebrovascular Diseases27(Suppl 1) (2009), 1–191.
24.
PatelN.V., GordonM.N., ConnorK.E., GoodR.A., EngelmanR.W., MasonJ., MorganD.G., MorganT.E. and FinchC.E., Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models, Neurobiology of Aging26 (2005), 995. doi:10.1016/j.neurobiolaging.2004.09.014.
25.
PierceA., UnwinR.D., EvansC.A., GriffithsS., CarneyL., ZhangL., JaworskaE., LeeC.F., BlincoD. and OkoniewskiM.J., Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases, Molecular & Cellular Proteomics7 (2008), 853. doi:10.1074/mcp.M700251-MCP200.
26.
QiJ.P., WuH., YangY., WangD.D., ChenY.X., GuY.H. and LiuT., Cerebral ischemia and Alzheimer's disease: The expression of amyloid-beta and apolipoprotein E in human hippocampus, Journal of Alzheimers Disease Jad12 (2007), 335–341. doi:10.3233/JAD-2007-12406.
27.
RabkinS.W., MathewsonA.L. and TateR.B., Predicting risk of ischemic heart disease and cerebrovascular disease from systolic and diastolic blood pressures, Annals of Internal Medicine88 (1978), 342–345. doi:10.7326/0003-4819-88-3-342.
28.
RenkawekK., StegeG.J. and BosmanG.J., Dementia, gliosis and expression of the small heat shock proteins hsp27 and alpha B-crystallin in Parkinson's disease, Neuroreport10 (1999), 2273. doi:10.1097/00001756-199908020-00009.
29.
RichensJ.L., SpencerH.L., ButlerM., CantlayF., VereK.A., BajajN., MorganK. and O'SheaP., Rationalising the role of keratin 9 as a biomarker for Alzheimer's disease, Scientific Reports6 (2016), 22962. doi:10.1038/srep22962.
30.
RossP.L., HuangY.N., MarcheseJ.N., WilliamsonB., ParkerK., HattanS., KhainovskiN., PillaiS., DeyS. and DanielsS., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents, Molecular & Cellular Proteomics Mcp3 (2004), 1154. doi:10.1074/mcp.M400129-MCP200.
31.
RothW., KumarV., BeerH.D., RichterM., WohlenbergC., ReuterU., ThieringS., Staratschek-JoxA., HofmannA. and KreuschF., Keratin 1 maintains skin integrity and participates in an inflammatory network in skin through interleukin-18, Journal of Cell Science125 (2012), 5269. doi:10.1242/jcs.116574.
32.
RudrabhatlaP., GrantP., JaffeH., StrongM.J. and PantH.C., Quantitative phosphoproteomic analysis of neuronal intermediate filament proteins (NF-M/H) in Alzheimer's disease by iTRAQ, Faseb J24 (2010), 4396–4407. doi:10.1096/fj.10-157859.
33.
SanthoshkumarP. and SharmaK.K., Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone, Molecular and Cellular Biochemistry267 (2004), 147–155. doi:10.1023/B:MCBI.0000049373.15558.b8.
34.
SaydoffJ.A., LiuL.S., GarciaR.A., HuZ., LiD. and von BorstelR.W., Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease, Brain Res994 (2003), 44–54. doi:10.1016/j.brainres.2003.09.049.
35.
SchwackeR.B.J.H., HillE.G., KrugE.L., Comte-WaltersS. and ScheyL.K., iQuantitator: A tool for protein expression inference using iTRAQ, BMC Bioinformatics10 (2009), 342. doi:10.1186/1471-2105-10-342.
36.
ShinoharaH., InagumaY., GotoS., InagakiT. and KatoK., Alpha B crystallin and HSP28 are enhanced in the cerebral cortex of patients with Alzheimer's disease, Journal of the Neurological Sciences119 (1993), 203–208. doi:10.1016/0022-510X(93)90135-L.
37.
SuL., CaoL., ZhouR., JiangZ., XiaoK., KongW., WangH., DengJ., WenB. and TanF., Identification of novel biomarkers for sepsis prognosis via urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS, PloS One8 (2013), e54237.
38.
TreumannA. and ThiedeB., Isobaric protein and peptide quantification: Perspectives and issues, Expert Rev Proteomics7 (2010), 647–653. doi:10.1586/epr.10.29.
39.
TschochnerH. and HurtE., Pre-ribosomes on the road from the nucleolus to the cytoplasm, Trends in Cell Biology13 (2003), 255. doi:10.1016/S0962-8924(03)00054-0.
40.
WapplerE.A., FelszeghyK., SzilágyiG., GálA., SkopálJ., MehraR.D., NyakasC. and NagyZ., Neuroprotective effects of estrogen treatment on ischemia-induced behavioural deficits in ovariectomized gerbils at different ages, Behavioural Brain Research209 (2010), 42–48. doi:10.1016/j.bbr.2010.01.010.
41.
WellerR.O., CohenN.R. and NicollJ.A., Cerebrovascular disease and the pathophysiology of Alzheimer's disease. Implications for therapy, Panminerva Medica46 (2004), 239–251.
42.
WilhelmusM.M., Otte-HöllerI., WesselingP., de WaalR.M., BoelensW.C. and VerbeekM.M., Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains, Neuropathol Appl Neurobiol32 (2006), 119–130. doi:10.1111/j.1365-2990.2006.00689.x.
43.
WilhelmusM.M.M., BoelensW.C., Otte-HöllerI., KampsB., KustersB., Maat-SchiemanM.L.C., WaalR.M.W.D. and VerbeekM.M., Small heat shock protein HspB8: Its distribution in Alzheimer's disease brains and its inhibition of amyloid-β protein aggregation and cerebrovascular amyloid-β toxicity, Acta Neuropathologica111 (2006), 139–149. doi:10.1007/s00401-005-0030-z.
44.
WunderlichM.T., EbertA.D., KratzT., GoertlerM., JostS. and HerrmannM., Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage, Stroke30 (1999), 1190–1195. doi:10.1161/01.STR.30.6.1190.
45.
ZhuH., BilginM. and SnyderM., Proteomics, Annual Review of Biochemistry72 (2003), 783–812. doi:10.1146/annurev.biochem.72.121801.161511.
